RxDoctor Payments DataLook up a doctor →

Christopher Watts, MD

Ophthalmology · Iowa City, IANPI 1457598641

Payments from drug & device makers

$4,085in general payments, 2019–2025

Across 175 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$828
  • Bausch Health US, LLC$308
  • Regeneron Healthcare Solutions, Inc.$297
  • Novartis$286
  • Bausch & Lomb Americas Inc.$182
  • plus $818 from 16 others

What the payments were for

  • Food & beverage$3,96097%
  • Education$802%
  • Gifts$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,085 in reported general payments places this provider in the 80th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$4,087,099
Medicare patients
2,400
Services billed
32,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,147$52,608
LumiganBimatoprost99$42,542
RestasisCyclosporine21$21,104
Restasis MultidoseCyclosporine11$13,119
CombiganBrimonidine Tartrate/Timolol22$6,650
Latanoprost634$5,606
Timolol Maleate194$4,264
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat141$2,457
Travoprost16$2,005
Loteprednol Etabonate14$1,731
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,466
Brimonidine Tartrate29$691
ValacyclovirValacyclovir Hcl15$503
Dorzolamide Hcl12$275
Ketorolac Tromethamine11$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Combigan$828$83,415153 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$37$1,73114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →